Semiconductors had the integrated circuit. The internet had a browser. Cloud computing had virtualization. AI had deep learning. And pharma? For decades, the industry has been extraordinarily good at one thing, finding new molecules. Better chemistry, better genomics, better computational screening. What it has not gotten meaningfully better at is knowing, ahead of time, how a human body will actually respond to any of it.

That gap between molecular discovery and human predictability is where Transcell Biologics has decided to bridge.

The Indian biotech company isn't chasing the next billion dollar molecule. It's chasing something more fundamental: the belief that the next real edge in drug development won't come from finding more molecules, but from understanding human biological response with far greater precision, long before a therapy ever reaches a patient. That belief has a name i.e. DART, or Digital Animal Replacement Technology, and it's less a lab tool than an argument about where the entire industry is headed.

Starting From a Different Question

Most biotech companies start with a therapeutic hypothesis. Transcell Biologics started with a systems-level one: what if drug development were built around actual human biology, instead of biological approximation? That question is what led to DART, an attempt to fuse laboratory science, computational biology, engineering and AI into one decision-support system, rather than treating each as its own silo.

The architecture runs four layers deep. First, human........

© Forbes India